Eleonora Teplinsky, MD, FASCO

Letter in @Nature_NPJ👉SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in #MetastaticBreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/42259831/ @BianchiniGP @breastoncdoc @JavierCortesMD @curijoey @Shaheenah1 @LGerratana @antgiorda @MIgnatiadis @KalinskyKevin @elmayermd @BCJoyceO @drsarahsam @PedramRazaviMD @PTarantinoMD @GustavoWerutsky #MBC

Please join us in Chicago at @COSMOCollab @WimedicineOrg Register at the below link wimedicine.org/wim-cosmo-2026 @oncologynursing

New ✨ Interlude Podcast episode with Ebonie Michelle, breast cancer survivor, patient advocate and Founder and CEO of Prowl The Lab. Ebonie empowers women and couples to reclaim their health and sexuality as they navigate disease, different-ability, and trauma. Her work highlights the connection between health, intimacy, body image, and overall well-being—topics that are so important, yet too often overlooked in cancer care. We talk about all of this today! 🎧 to Interlude wherever you get your podcasts or on YouTube!

Tickets are now available for the Beyond The Pink Book Launch, written by @drteplinsky. This event will be on Thursday, October 8th at the Tarrytown House Estate in New York. Click here: BeyondThePink.givesmart.com for event details and tickets!

@AbiSivaMD @maryam_lustberg 100%. We can use low dose vaginal estrogen and its use in patients w breast cancer is supported by multiple guidelines. Also helpful to see this new data! Low dose vaginal estrogen can be incredibly beneficial for so many of our patients.

This is a common question that we battle in our clinics every day. A good risk-benefit discussion and review of the existing data gives reassurance to try low potency topical estrogen after failing non-hormonal products. @maryam_lustberg @drteplinsky

We are thrilled to be hosting a book launch for @drteplinsky and her new book, Beyond The Pink! Make sure to save the date and stay tuned for event registration, opening next week!

ctDNA positivity is now a prognostic marker across tumor types, with bladder cancer carrying the strongest predictive evidence after IMvigor011. John Strickler, MD, Eleonora Teplinsky, MD, Benjamin Weinberg, MD, Petros Grivas, MD, PhD, and Luis E. Raez, MD break down the data. Watch the full OncLive® Peer Exchange: hubs.ly/Q04ms9JF0 @drteplinsky @ValleyHealthNJ @benweinbergmd @LombardiCancer @PGrivasMDPhD @fredhutch @LuisRaezMD @MCIStrong #ctDNA #MRDTesting #SolidTumors

We have a new Clinical Notice recommending against ivermectin & fenbendazole for cancer treatment outside of clinical trials. Read more: bit.ly/4oCmGWT

This is going to be an incredible event with @InfiniteMBC!! Thank you and can’t wait! 🩷🩷

Dr. John Strickler discusses circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing across solid tumors with @drteplinsky (@ValleyHealthNJ), @benweinbergmd (@LombardiCancer ), @PGrivasMDPhD (@fredhutch), and @LuisRaezMD (Memorial Healthcare System). onclive.com/view/foundatio… @OncLive

And, for any clinician who thinks/believes or tells patients they’re too young to have breast cancer - this is worth a watch. Brittany Beadle - diagnosed at age 18 with MBC - just passed away at age 29 from the same disease she was initially told she was too young to have. fb.watch/HOnrR-_VhV/?fs…

@COlazagasti @NazliDizman @SylvesterCancer @GlopesMd @DrTracyECrane @NarjustFlorezMD @Latinamd @DrFrankJPenedo @KobetzErin @LaurenGroner @DrSDNimer Congrats!!!!

A milestone I'll never forget: recipient of the Florida Innovation Award with $1M+ in funding. THIS is validation that improving access to early LC detection is worth fighting for. Deeply grateful to my mentors, collaborators, and the incredible team that made this possible.

The last point is that what the #OPTIMA trial hammered home is the we truly overprescribe chemotherapy (especially anthracycline based chemo) to ER+ breast cancer patients and in that molecularly low risk 40+ patient population ovarian suppression and aromatase inhibitor is just as effective as chemo and less toxic. Our field needs to move towards de-escalating chemotherapy in ER+ disease (including premenopausal) and utilizing targeted therapy (ovarian suppression and aromatase inhibitors are some of the 1st targeted therapies). No more overuse of chemo in this population. It doesn't help!

📣COME JOIN this NEW innovative open discussion format, no didactics, just practice changing exchange. enjoy food/drinks & maybe win the raffle! Libretto 432 Harmoni 6 Crown Atypical EGFR ADC updates Tarla & more ⏱️ 6/10 wed 6-8:40 pm @mjeng21 @MSKCancerCenter @MSK_DeptOfMed

roche.com/media/releases… FDA expected to make decision on girdestrant in early stage BC by November 30, 2026!

@tess_omeara I wonder if many people had left ASCO by then or if there was a competing session. The session on Sunday on AI and the Information Gap had a packed room!! I heard they were turning people away so there’s def interest!!

I can’t imagine there are many conferences outside of clinical Oncology where the AI session looks like this (>40k ppl at #ASCO26). I think Oncologists know there are challenges to be worked out before AI impacts tx decisions, but I’m excited to see this change in my career

So excited to share that my book is out on 9/29/2026!! Pre-order here a.co/d/0bdFkY8Q 🩷

From chemotherapy de-escalation and oral SERDs to metastatic triple-negative breast cancer and GLP-1 medicines, @drteplinsky breaks down some of the biggest breast cancer research updates from #ASCO26, what they could mean for breast cancer care, and the questions researchers are still working to answer. 🎧 Listen now: bit.ly/4dTmk9r #ASCO26 #BreastCancer #CancerResearch #BreastCancerWarrior

Practice-changing de-escalation data from REDUSE 96/12 at #ASCO2026. • Phase III non-inferiority trial (N=1380); 57% had metastatic breast cancer • Denosumab 120 mg Q12W after induction vs standard Q4W • Calcium 500 mg + Vitamin D 400 IU daily mandated Key findings: • Q12W was non-inferior for prevention of symptomatic skeletal events (56.5 vs 56.6 months; HR 1.02) • Lower rates of hypocalcemia (HR 0.70) • ~25% reduction in ONJ • Swiss analysis showed a 53% reduction in costs, likely even greater in the US This study reinforces my current practice of extending denosumab dosing intervals. Less treatment, lower toxicity, lower cost, and no loss of efficacy. #BreastCancer #BoneMetastases #Denosumab #ASCO2026 @muschollings